A randomized, phase III multicenter trial of gemcitabine in combination with carboplatin or paclitaxel versus paclitaxel plus carboplatin in patients with advanced or metastatic non-small-cell lung cancer

Treat, Joseph; Gonin, René; Socinski, Mark A.; Edelman, Martin J.; Catalano, Robert B.; Marinucci, D. M.; Ansari, Rafat; Gillenwater, Heidi H.; Rowland, Kendrith M.; Comis, Robert L.; Obasaju, Coleman K.; Belani, Chandra P.

doi:10.1093/annonc/mdp352

Cited by 57 publications

(86 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In general, the incidence of grades 3 and 4 aes was higher with gemcitabine-carboplatin than with other regimens, but sb-paclitaxel-containing regimens resulted in a higher incidence of grades 3 and 4 sensory neuropathy 34 .…”

Section: Taxanes In Combination With Other Thirdgeneration Chemotheramentioning

confidence: 85%

“…Accordingly, the efficacy and safety of taxanes in combination with other third-generation chemotherapy agents such as gemcitabine and vinorelbine have also been assessed [31][32][33][34][35] .…”

Section: Taxanes In Combination With Other Thirdgeneration Chemotheramentioning

confidence: 99%

“…Until recently, histology was not generally considered when treatment decisions were made 5 . Few phase iii studies have assessed outcome by histology; however, subanalyses of such trials are beginning to surface in light of histology's growing importance (Table ii Recently, a phase iii trial conducted by Treat and colleagues in patients with advanced nsclc treated with gemcitabine-carboplatin, gemcitabine-sbpaclitaxel, or sb-paclitaxel-carboplatin was retrospectively analyzed 33,34 . No difference in orr was noted for patients with nonsquamous histology, but compared with gemcitabine-carboplatin, sb-paclitaxel-carboplatin was associated with a significantly greater orr in patients with scc (46% vs. 25%, p = 0.02) 33 .…”

Section: Taxanes and Histologymentioning

confidence: 99%

See 2 more Smart Citations

Update on Taxanes in the First-Line Treatment of Advanced Non-Small-Cell Lung Cancer

Socinski¹

2014

Current Oncology

Self Cite

View full text Add to dashboard Cite

standard-of-care options, and no single standardof-care regimen is superior in the treatment of advanced nsclc 7-10 . Thus, physicians rely on numerous factors to optimize treatment strategies, including histology, age, performance status, cost, tolerability, and convenience. The combination of a platinum agent with a taxane-either solvent-based (sb) paclitaxel (Taxol: Bristol-Myers Squibb, Princeton, NJ, U.S.A.) or docetaxel (Taxotere: SanofiAventis, Bridgewater, NJ, U.S.A.)-has a proven efficacy and safety profile in advanced nsclc 6 . The sb-paclitaxel-carboplatin regimen is among those most commonly used for the first-line treatment of advanced nsclc in the United States 11 .Recently, nab-paclitaxel, a 130-nm albuminbound ("nab") form of paclitaxel designed to use endogenous albumin pathways to increase intratumoural concentrations of the active drug, demonstrated improved antitumour activity and tolerability compared with sb-paclitaxel when both were used in combination with carboplatin in the first-line treatment of patients with advanced nsclc 12 . Based on the results of a phase iii trial, nab-paclitaxel in combination with carboplatin was approved in 2012 as first-line therapy for the treatment of locally advanced or metastatic nsclc in patients who are not candidates for curative surgery or radiation therapy 12,13 . The present review summarizes the clinical experience to date with taxanes in the first-line treatment of nsclc. DISCUSSION Taxane-Platinum CombinationsIn landmark nsclc studies, overall response rates (orrs) were higher with taxane-platinum combinations than with other chemotherapy regimens ( Table i). Historically, sb-paclitaxel given in combination with carboplatin or cisplatin demonstrated a median overall survival (os) of 7.7-10 months and an orr of 17%-41% [7][8][9]11,14,[16][17][18]22 . ABSTRACTBased on demonstrated favourable risk-benefit profiles, taxanes remain a key component in the first-line standard of care for advanced non-smallcell lung cancer (nsclc) and nsclc subtypes. In 2012, a novel taxane, nab-paclitaxel (Abraxane: Celgene Corporation, Summit, NJ, U.S.A.), was approved, in combination with carboplatin, for the first-line treatment of locally advanced or metastatic nsclc. The approval was granted because of demonstrated improved antitumour activity and tolerability compared with solvent-based paclitaxelcarboplatin in a phase iii trial. This review focuses on the evolution of first-line taxane therapy for advanced nsclc and the new options and advances in taxane therapy that might address unmet needs in advanced nsclc.

show abstract

Section: Taxanes In Combination With Other Thirdgeneration Chemotheramentioning

confidence: 85%

Section: Taxanes In Combination With Other Thirdgeneration Chemotheramentioning

confidence: 99%

Section: Taxanes and Histologymentioning

confidence: 99%

See 1 more Smart Citation

Update on Taxanes in the First-Line Treatment of Advanced Non-Small-Cell Lung Cancer

Socinski¹

2014

Current Oncology

Self Cite

View full text Add to dashboard Cite

show abstract

“…The first of these studies was conducted by the Italian Lung Cancer Project (ILCP) and consisted of 612 patients who were enrolled at 1 of 31 Italian institutions between August 1998 and May 2000 [7]. The second study was conducted by the Alpha Oncology Research Network and consisted of 1135 patients who were enrolled at 1 of 80 investigative centers in the United States between July 2000 and November 2005 [20]. The third study was conducted in 26 countries globally at 177 investigative centers and consisted of 1725 patients who were enrolled between July 2004 and December 2005 [10].…”

Section: Methodsmentioning

confidence: 99%

Comparison of pemetrexed plus cisplatin with other first-line doublets in advanced non-small cell lung cancer (NSCLC): A combined analysis of three phase 3 trials

et al. 2012

View full text Add to dashboard Cite

“…In the last decade, the me-dian overall survival of the patients with metastatic NSCLC treated systemically within clinical studies, have grown from a few months to more than 20 months as reported in some studies results [4][5][6][7]. This improvement was obtained thanks not only to the modification of the previous treatment regimens [8][9][10][11], but first of all thanks to the application of new drugs, such as epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKI) and ALK inhibitors [12][13][14][15][16][17][18][19][20].…”

Section: Introductionmentioning

confidence: 99%

The results of first line systemic therapy of NSCLC in clinical practice

Adamowicz¹

2017

Nowotwory. Journal of Oncology

View full text Add to dashboard Cite

Introduction. Lung cancer is the most common cancer in the world. Every year, there are over 1.4 million new cases and about 1.3 million deaths due to lung cancer. Data on the results of palliative treatment of patients with non-small cell lung cancer in Poland are scarce. Methods. The results of first-line palliative chemotherapy in 204 lung cancer patients treated in the period 2011-2014 in two cancer centres were analysed. Results. The mean age of the study group was 63.4 ± 8.3 years; 155 patients received chemotherapy with cisplatin, 33 -schemes containing carboplatin, 8 -inhibitors of EGFR tyrosine kinase, 8 -vinorelbine or gemcitabine monotherapy. Complete regression was observed in 2 patients, partial response -in 52 patients (25%), stable disease in 92 (45%) and 58 (28%) patients had progression. Median survival for the entire group of patients was 12 months. Multidrug chemotherapy with cisplatin compared with chemotherapy involving carboplatin monotherapy was associated with increased toxicity in total (p = 0.04). An increased toxicity concerned only to haematological complications and renal insufficiency expressed by the level of creatinine in blood serum. There was no apparent effect of chemotherapy on the overall quality of life. Conclusions. The results of palliative treatment of non-small cell lung cancer in daily practice are comparable to those obtained in prospective clinical trials despite having a different population of treated patients. The use of palliative chemotherapy had no significant effect on quality of life. NOWOTWORY J Oncol 2017; 67, 1: 24-33

show abstract

A randomized, phase III multicenter trial of gemcitabine in combination with carboplatin or paclitaxel versus paclitaxel plus carboplatin in patients with advanced or metastatic non-small-cell lung cancer

Cited by 57 publications

References 49 publications

Update on Taxanes in the First-Line Treatment of Advanced Non-Small-Cell Lung Cancer

Update on Taxanes in the First-Line Treatment of Advanced Non-Small-Cell Lung Cancer

Comparison of pemetrexed plus cisplatin with other first-line doublets in advanced non-small cell lung cancer (NSCLC): A combined analysis of three phase 3 trials

The results of first line systemic therapy of NSCLC in clinical practice

Contact Info

Product

Resources

About